Last updated: February 14, 2026
What is the drug with NDC 00310-0284?
The NDC 00310-0284 corresponds to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor approved by the FDA for rheumatoid arthritis and other autoimmune conditions. It is marketed by Pfizer.
Current market landscape
Therapeutic area: Autoimmune diseases, primarily rheumatoid arthritis (RA). Also approved for psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis.
Market size: The global RA market was valued at approximately USD 21.2 billion in 2021. Xeljanz's share of this segment is significant, with USD 2.7 billion in global sales in 2022.
Competitive landscape: Existing competitors include:
- Abatacept (Orencia)
- Tocilizumab (Actemra)
- Baricitinib (Olumiant)
- Upadacitinib (Rinvoq)
Market penetration: Xeljanz holds roughly 13% of the RA biologic and advanced therapy market worldwide. Its oral route offers a competitive advantage over injectable biologics.
Regulatory status: Approved in multiple countries; in the U.S., FDA approval for RA was granted in 2012. Label expansions occurred in subsequent years for additional indications.
Price points and reimbursement landscape
Current pricing:
-
In the U.S., Xeljanz (tofacitinib) is priced at approximately USD 1,950 per month for the 5 mg twice daily dose.
-
Cost per year: roughly USD 23,400, though actual patient out-of-pocket varies with insurance and assistance programs.
Reimbursement: Widely covered by private insurers and Medicare. Biosimilar competition remains limited but could influence pricing.
Factors influencing future price projections
-
Patent expiration and biosimilar entry: The patent on Xeljanz is expected to expire in 2025, with biosimilar or generic tofacitinib entering the market potentially reducing prices by 30-50% within 1-3 years post-expiry.
-
Approval of alternative JAK inhibitors: New entrants like upadacitinib (AbbVie) and baricitinib (Eli Lilly) intensify competition, potentially pressuring Xeljanz prices downward.
-
Regulatory developments: Approval for additional indications (e.g., inflammatory bowel disease) may sustain or elevate pricing based on market size expansion.
-
Market penetration of biosimilars: Limited biosimilar presence for tofacitinib currently; emergence could significantly alter pricing strategies.
-
Reimbursement and pricing policies: U.S. and European price controls could influence list prices and discounts.
Price projections (2024-2030)
| Year |
Estimated Average Price per Month |
Rationale |
Notes |
| 2024 |
USD 1,800 - 2,000 |
Post-patent expiry, initial biosimilar entry begins |
Price reduction after patent expiry begins; discounts increasing |
| 2025 |
USD 1,500 - 1,700 |
Biosimilar market penetration accelerates |
Significant competition impacts list prices |
| 2026 |
USD 1,200 - 1,400 |
Market stabilization with multiple biosimilar options |
Price reductions stabilize; value-based pricing strategies adopted |
| 2027-2030 |
USD 1,000 - 1,200 |
Continued biosimilar expansion, new indications, price negotiations |
Potential for further discounts; development of value-based agreements |
Key market trends
-
The biosimilar pathway for small molecules like tofacitinib remains complex; biosimilar approvals could influence price reductions but may face regulatory delays.
-
Shift to value-based pricing may moderate price erosion. Payers increasingly favor outcomes-based contracts.
-
Expansion into new indications will help sustain revenue but do not significantly impact pricing directly.
-
Patient access programs and co-pay assistance programs mitigate high drug prices, influencing overall revenue.
Summary
The market value of NDC 00310-0284 (Xeljanz) peaks around 2022, with global sales nearing USD 2.7 billion. Post-patent expiry—expected in 2025—prices are projected to decline by approximately 20-30% in the immediate years following. Continued competition from other oral JAK inhibitors and biosimilars will exert further downward pressure, potentially reducing prices by half by 2030. The pace and extent of price declines depend on regulatory developments, biosimilar market entry, and payor dynamics.
Key Takeaways
-
Xeljanz is a leading oral JAK inhibitor with substantial market share in autoimmune diseases.
-
Its premium pricing is approximately USD 1,950/month in the U.S., with significant room for reduction post-patent expiration.
-
Entry of biosimilars after 2025 is expected to reduce prices by at least 30%, with further declines possible as competition and biosimilar proliferation increase.
-
Market growth is driven by expanded indications, although pricing pressures will intensify, especially in price-sensitive markets.
-
Ongoing negotiations, policy changes, and biosimilar advances are primary factors shaping future pricing.
FAQs
-
When will biosimilars for tofacitinib likely enter the market?
Biosimilar approvals are anticipated around 2024-2025, post-patent expiration, with market entry potentially occurring within 6-12 months.
-
How much could prices decrease after biosimilar entry?
Prices could fall by 30-50%, depending on market competition and payer negotiations.
-
Are there regulatory barriers to biosimilar development for small molecules like tofacitinib?
Biosimilars typically apply to biologics; as a small molecule, generic versions of tofacitinib are more straightforward and may enter the market sooner, with greater price reduction potential.
-
What impact does market competition have on the price of Xeljanz?
Competition from other oral JAK inhibitors and potential generics drives prices downward, especially in highly regulated markets.
-
Will new indications significantly affect the drug’s revenue?
Additional approved indications can help maintain revenue levels but are less influential on price than patent expiry or biosimilar entry.
References
- IQVIA. “Global Rheumatoid Arthritis Market Review.” 2022.
- U.S. Food and Drug Administration. “Xeljanz (tofacitinib) approval and label updates.” 2012-2022.
- Pfizer. “Xeljanz Product Monograph.” 2022.
- Evaluate Pharma. “Market forecasts for autoimmune therapies.” 2022.
- Statista. “Global biosimilar and generic drug market data.” 2022.
